Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Dignass

Showing results (101-110 of 177) with videos related to

Pageof 18
Sort By:
Journal of Crohn'S & Colitis|October 9, 2012
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosisAxel Dignass, Rami Eliakim, Fernando Magro, et al.
Inflammatory Bowel Diseases|August 7, 2023
Disease Clearance as a New Outcome in Ulcerative Colitis: a Systematic Review and Expert ConsensusFerdinando D'Amico, Fernando Magro, Britta Siegmund, et al.
United European Gastroenterology Journal|May 4, 2023
Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: Results up to Week 104 of the STARDUST trialJulian Panés, Séverine Vermeire, Geert R D'Haens, et al.
United European Gastroenterology Journal|March 6, 2023
Has the therapeutical ceiling been reached in Crohn's disease randomized controlled trials? A systematic review and meta-analysisFernando Magro, Paula Leão Moreira, Gaia Catalano, et al.
Medicina (Kaunas, Lithuania)|January 21, 2023
International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult PatientsBénédicte Caron, Vipul Jairath, Ferdinando D'Amico, et al.
Journal of Crohn'S & Colitis|March 27, 2026
Timing matters: recommendations for outcome assessment in real-world evidence studies of Crohn's diseasePaula Leão Moreira, Axel Dignass, Maria Manuela Estevinho, et al.
Journal of Crohn'S & Colitis|May 11, 2026
Mirikizumab is associated with rapid and sustained improvements in novel measures of bowel urgency in moderately-to-severely active ulcerative colitis: 28-week results from the LUCENT-URGE trialSilvio Danese, Axel Dignass, David Laharie, et al.
Journal of Gastroenterology and Hepatology|June 9, 2020
"It ain't over … till it's over!" Risk-mitigation strategies for patients with gastrointestinal diseases in the aftermath of the COVID-19 pandemicGerald Holtmann, Eamonn M Quigley, Ayesha Shah, et al.
Journal of Crohn'S & Colitis|July 22, 2025
Comparison of the FDA and EMA guidance on drug development in ulcerative colitis: an expert panel reviewSophie Vieujean, Bruce E Sands, Remo Panaccione, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|April 7, 2024
Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensusPablo A Olivera, Axel Dignass, Marla C Dubinsky, et al.
Pageof 18

Showing results (101-110 of 177) with videos related to

Sort By:
Pageof 18
Journal of Crohn'S & Colitis|October 9, 2012
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosisAxel Dignass, Rami Eliakim, Fernando Magro, et al.
Inflammatory Bowel Diseases|August 7, 2023
Disease Clearance as a New Outcome in Ulcerative Colitis: a Systematic Review and Expert ConsensusFerdinando D'Amico, Fernando Magro, Britta Siegmund, et al.
United European Gastroenterology Journal|May 4, 2023
Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: Results up to Week 104 of the STARDUST trialJulian Panés, Séverine Vermeire, Geert R D'Haens, et al.
United European Gastroenterology Journal|March 6, 2023
Has the therapeutical ceiling been reached in Crohn's disease randomized controlled trials? A systematic review and meta-analysisFernando Magro, Paula Leão Moreira, Gaia Catalano, et al.
Medicina (Kaunas, Lithuania)|January 21, 2023
International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult PatientsBénédicte Caron, Vipul Jairath, Ferdinando D'Amico, et al.
Journal of Crohn'S & Colitis|March 27, 2026
Timing matters: recommendations for outcome assessment in real-world evidence studies of Crohn's diseasePaula Leão Moreira, Axel Dignass, Maria Manuela Estevinho, et al.
Journal of Crohn'S & Colitis|May 11, 2026
Mirikizumab is associated with rapid and sustained improvements in novel measures of bowel urgency in moderately-to-severely active ulcerative colitis: 28-week results from the LUCENT-URGE trialSilvio Danese, Axel Dignass, David Laharie, et al.
Journal of Gastroenterology and Hepatology|June 9, 2020
"It ain't over … till it's over!" Risk-mitigation strategies for patients with gastrointestinal diseases in the aftermath of the COVID-19 pandemicGerald Holtmann, Eamonn M Quigley, Ayesha Shah, et al.
Journal of Crohn'S & Colitis|July 22, 2025
Comparison of the FDA and EMA guidance on drug development in ulcerative colitis: an expert panel reviewSophie Vieujean, Bruce E Sands, Remo Panaccione, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|April 7, 2024
Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensusPablo A Olivera, Axel Dignass, Marla C Dubinsky, et al.
Pageof 18